ICCM News & Events

IceCure Medical intends to effect a one-for-thirty reverse split of the company's ordinary shares, no par value per share, as part of its proactive efforts to regain compliance with the Nasdaq $1.00 minimum bid price requirement and support its broader capital markets strategy. The ordinary shares continue to trade on the Nasdaq Capital Market under the existing symbol "ICCM" and will begin trading on a split-adjusted basis when the market opens on June 4. The new CUSIP number for the ordinary shares following the reverse share split will be M53071201. The primary purpose of the reverse share split is to increase the per-share trading price of the company's ordinary shares to regain compliance with the $1.00 minimum bid price requirement for continued listing on Nasdaq. Under applicable Nasdaq rules, the company has until November 9 to cure the non-compliance. By effecting the reverse share split at this time, the Company intends to proactively satisfy these regulatory requirements and maintain the listing of its ordinary shares on Nasdaq. The split will adjust the number of ordinary shares from 84,201,034 to approximately 2,806,701.

Reports Q1 revenue $911K, consensus $1.34M. "We are off to an incredibly strong start to 2026 and we are highly encouraged by the growing momentum we are experiencing in the U.S. for ProSense in early-stage breast cancer, which has been building over time through our clinical data, physician engagement, and regulatory milestones," said CEO Eyal Shamir. "Our commercial team is building a strong pipeline of hospitals and clinics, many of which are progressing through their internal purchasing processes, and we are now seeing that pipeline converting into revenue...We plan to leverage this rising interest and expand our U.S. sales footprint this year to eight regions, supporting the increasing demand from our marketing efforts and heightened positive response to our presence at key recent industry conferences... ProSense integrates seamlessly into existing clinical workflows without requiring additional infrastructure, so we believe we are well positioned to scale. We also expect our ChoICE post-marketing study, which will include 30 U.S. sites and where both commercial and clinical procedures will be performed, will further accelerate adoption and broaden access to ProSense across the U.S."